Galderma Laboratories Patent-Cliff Exposure & CMS Drug Spending Portfolio

Galderma Laboratories (Fort Worth, TX): 8 reconciled FDA prescription therapies (51.0% 2025 to 2030 cliff risk), $6.6M 2024 CMS Part D & Medicaid spend, and $4,240 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterFort Worth, TX
Reconciled FDA Portfolio Therapies8
2025 to 2030 Patent-Cliff Revenue Exposure51.0%
Primary Portfolio LOE Date2027-01-01
2024 CMS Total Public Spend$6.6M
2024 Medicare Part D Spend$6.4M
2024 Medicaid Spend$162K
California HCAI SB 17 FilingsSpecialty launch notice ($4,240 intro WAC)